Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/7/2018
University of Colorado Cancer Center
mi
from
Aurora, CO
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/7/2018
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/7/2018
University of Michigan
mi
from
Ann Arbor, MI
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/7/2018
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/7/2018
Duke Cancer Center
mi
from
Durham, NC
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/7/2018
Duke Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/7/2018
M.D. Anderson Cancer Center
mi
from
Houston, TX
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/7/2018
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/7/2018
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/7/2018
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/7/2018
Mayo Clinic Cancer Center
mi
from
Jacksonville, FL
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/7/2018
Mayo Clinic Cancer Center
mi
from
Jacksonville, FL
Click here to add this to my saved trials
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/7/2018
Northwestern University - Robert H Lurie Comprehensive Cancer Center
mi
from
Chicago, IL
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/7/2018
Northwestern University - Robert H Lurie Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/7/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/7/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/7/2018
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/7/2018
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/7/2018
University of Washington/Seattle Cancer Care Alliance
mi
from
Seattle, WA
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/7/2018
University of Washington/Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/7/2018
The Mayo Clinic
mi
from
Rochester, MN
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/7/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial
Status: Enrolling
Updated:  2/8/2018
Presbyterian - Saint Lukes Medical Center - Health One
mi
from
Denver, CO
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial
Status: Enrolling
Updated: 2/8/2018
Presbyterian - Saint Lukes Medical Center - Health One
mi
from
Denver, CO
Click here to add this to my saved trials
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial
Status: Enrolling
Updated:  2/8/2018
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial
Status: Enrolling
Updated: 2/8/2018
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial
Status: Enrolling
Updated:  2/8/2018
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial
Status: Enrolling
Updated: 2/8/2018
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial
Status: Enrolling
Updated:  2/8/2018
LDS Hospital
mi
from
Salt Lake City, UT
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial
Status: Enrolling
Updated: 2/8/2018
LDS Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial
Status: Enrolling
Updated:  2/8/2018
Veterans Administration Center-Seattle
mi
from
Seattle, WA
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial
Status: Enrolling
Updated: 2/8/2018
Veterans Administration Center-Seattle
mi
from
Seattle, WA
Click here to add this to my saved trials
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial
Status: Enrolling
Updated:  2/8/2018
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial
Status: Enrolling
Updated: 2/8/2018
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial
Status: Enrolling
Updated:  2/8/2018
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial
Status: Enrolling
Updated: 2/8/2018
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial
Status: Enrolling
Updated:  2/8/2018
Rigshospitalet University Hospital
mi
from
Copenhagen,
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial
Status: Enrolling
Updated: 2/8/2018
Rigshospitalet University Hospital
mi
from
Copenhagen,
Click here to add this to my saved trials
Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Dose Escalation Study of Clofarabine in Combination With Cytarabine (Ara-C) and G-CSF Priming for Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients
Status: Enrolling
Updated:  2/8/2018
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Dose Escalation Study of Clofarabine in Combination With Cytarabine (Ara-C) and G-CSF Priming for Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients
Status: Enrolling
Updated: 2/8/2018
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)
A Phase II Study of Omacetaxine (OM) and Decitabine (DAC) in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  2/9/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)
A Phase II Study of Omacetaxine (OM) and Decitabine (DAC) in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 2/9/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated:  2/11/2018
Stanford University Medical Center, Division of Hematology
mi
from
Stanford, CA
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated: 2/11/2018
Stanford University Medical Center, Division of Hematology
mi
from
Stanford, CA
Click here to add this to my saved trials
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated:  2/11/2018
Hartford Hospital Cancer Clinical Research Office
mi
from
Hartford, CT
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated: 2/11/2018
Hartford Hospital Cancer Clinical Research Office
mi
from
Hartford, CT
Click here to add this to my saved trials
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated:  2/11/2018
Cleveland Clinic Florida, Department of Clinical Research
mi
from
Weston, FL
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated: 2/11/2018
Cleveland Clinic Florida, Department of Clinical Research
mi
from
Weston, FL
Click here to add this to my saved trials
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated:  2/11/2018
Indianapolis University Cancer Center
mi
from
Indianapolis, IN
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated: 2/11/2018
Indianapolis University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated:  2/11/2018
Johns Hopkins University Medical Center
mi
from
Baltimore, MD
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated: 2/11/2018
Johns Hopkins University Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated:  2/11/2018
National Heart, Lung, and Blood Institute, National Institutes of Health
mi
from
Bethesda, MD
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated: 2/11/2018
National Heart, Lung, and Blood Institute, National Institutes of Health
mi
from
Bethesda, MD
Click here to add this to my saved trials
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated:  2/11/2018
Massachusetts General Hospital
mi
from
Boston, MA
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated: 2/11/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated:  2/11/2018
Mayo Clinic, Divison of Hematology
mi
from
Rochester, MN
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated: 2/11/2018
Mayo Clinic, Divison of Hematology
mi
from
Rochester, MN
Click here to add this to my saved trials
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated:  2/11/2018
Washington University, Department of Internal Medicine/Division of Hematology
mi
from
Saint Louis, MO
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated: 2/11/2018
Washington University, Department of Internal Medicine/Division of Hematology
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated:  2/11/2018
NYU Clinical Cancer Center
mi
from
New York, NY
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated: 2/11/2018
NYU Clinical Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated:  2/11/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated: 2/11/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated:  2/11/2018
Duke University Medical Center, Division Cell Therapy, Heme Malignancies Program
mi
from
Durham, NC
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated: 2/11/2018
Duke University Medical Center, Division Cell Therapy, Heme Malignancies Program
mi
from
Durham, NC
Click here to add this to my saved trials
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated:  2/11/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated: 2/11/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated:  2/11/2018
Presbyterian Medical Center, PENN Comprehensive Hemophilia & Thombosis Program
mi
from
Philadelphia, PA
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated: 2/11/2018
Presbyterian Medical Center, PENN Comprehensive Hemophilia & Thombosis Program
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated:  2/11/2018
Royal North Shore Hospital, Haematology Department
mi
from
Saint Leonards,
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status: Enrolling
Updated: 2/11/2018
Royal North Shore Hospital, Haematology Department
mi
from
Saint Leonards,
Click here to add this to my saved trials
Fabry Screening Study
Expanded Screening for Fabry Trait
Status: Enrolling
Updated:  2/12/2018
Baylor Institute of Metabolic Disease
mi
from
Dallas, TX
Fabry Screening Study
Expanded Screening for Fabry Trait
Status: Enrolling
Updated: 2/12/2018
Baylor Institute of Metabolic Disease
mi
from
Dallas, TX
Click here to add this to my saved trials
CART-19 for Multiple Myeloma
Pilot Study Of Redirected Autologous T Cells Engineered To Contain Anti-CD19 Attached To TCRζ And 4-1BB Signaling Domains Coupled With Salvage Autologous Stem-Cell Transplantation (ASCT) In Multiple Myeloma Patients With Early Relapse/Progression After Initial ASCT
Status: Enrolling
Updated:  2/12/2018
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
CART-19 for Multiple Myeloma
Pilot Study Of Redirected Autologous T Cells Engineered To Contain Anti-CD19 Attached To TCRζ And 4-1BB Signaling Domains Coupled With Salvage Autologous Stem-Cell Transplantation (ASCT) In Multiple Myeloma Patients With Early Relapse/Progression After Initial ASCT
Status: Enrolling
Updated: 2/12/2018
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  2/12/2018
Clinical Research Facility
mi
from
Birmingham, AL
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 2/12/2018
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  2/12/2018
Clinical Research Facility
mi
from
Scottsdale, AZ
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 2/12/2018
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  2/12/2018
Clinical Research Facility
mi
from
Baldwin Park, CA
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 2/12/2018
Clinical Research Facility
mi
from
Baldwin Park, CA
Click here to add this to my saved trials
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  2/12/2018
Clinical Research Facility
mi
from
Bellflower, CA
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 2/12/2018
Clinical Research Facility
mi
from
Bellflower, CA
Click here to add this to my saved trials
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  2/12/2018
Clinical Research Facility
mi
from
Beverly Hills, CA
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 2/12/2018
Clinical Research Facility
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  2/12/2018
Clinical Research Facility
mi
from
Corona, CA
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 2/12/2018
Clinical Research Facility
mi
from
Corona, CA
Click here to add this to my saved trials
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  2/12/2018
Clinical Research Facility
mi
from
Fullerton, CA
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 2/12/2018
Clinical Research Facility
mi
from
Fullerton, CA
Click here to add this to my saved trials
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  2/12/2018
Clinical Research Facility
mi
from
Highland, CA
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 2/12/2018
Clinical Research Facility
mi
from
Highland, CA
Click here to add this to my saved trials
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  2/12/2018
Clinical Research Facility
mi
from
La Jolla, CA
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 2/12/2018
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  2/12/2018
Clinical Research Facility
mi
from
Los Angeles, CA
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 2/12/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  2/12/2018
Clinical Research Facility
mi
from
Orange, CA
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 2/12/2018
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  2/12/2018
Clinical Research Facility
mi
from
Palo Alto, CA
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 2/12/2018
Clinical Research Facility
mi
from
Palo Alto, CA
Click here to add this to my saved trials